Evidence map›Paper›PMID 31396241›Full record

ReviewFrontiers in immunology2019

From Natural Killer Cell Receptor Discovery to Characterization of Natural Killer Cell Defects in Primary Immunodeficiencies.

Giovanna Tabellini, Ornella Patrizi, Kerry Dobbs, Vassilios Lougaris, Manuela Baronio, Daniela Coltrini, Alessandro Plebani, Raffaele Badolato, Luigi D Notarangelo, Silvia Parolini

Open access · goldAbstract readHistorical ArticleReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Giovanna TabelliniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Ornella PatriziDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Kerry DobbsLaboratory of Host Defenses, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Vassilios LougarisDepartment of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy.
Manuela BaronioDepartment of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy.
Daniela ColtriniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Alessandro PlebaniDepartment of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy.
Raffaele BadolatoDepartment of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy.
Luigi D NotarangeloLaboratory of Host Defenses, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Silvia ParoliniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
University of Brescia · ITNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alessandro Moretta was Professor of Histology at University of Brescia from 1994 to 1997. It was in that period that we met and started a collaboration that continued in the years to follow. He immediately involved us in the production of monoclonal antibodies (mAbs) that allowed the identification and fine characterization of novel receptor molecules that were able to activate or inhibit human Natural Killer cell function, including several antibodies specific for Natural Cytotoxicity Receptor (NCR) and Killer-cell Immunoglobulin-like Receptor (KIR) molecules. These reagents, generated in our laboratory in Brescia, contributed to complete the studies aimed to characterize innate lymphoid NK cells, that had been initiated by Alessandro and his brother Lorenzo in Genoa. Soon, we identified an anti-KIR3DL2 that was subsequently shown to be helpful for the diagnosis and treatment of various forms of cutaneous T cell lymphoma. While in Brescia, Alessandro established a partnership with those of us who were working in the Department of Pediatrics; together, in short time we tackled the goal of studying the role of NK cells in patients with primary immunodeficiencies. This collaboration led to novel discoveries that shed light on the critical role played by NK cells in the immune response against virus and tumors in humans, as best exemplified by our characterization of the molecular mechanisms of impaired control of Epstein-Barr Virus (EBV) infection in patients with X-linked lymphoproliferative (XLP) disease. After Alessandro left Brescia to return to Genoa, our collaboration continued with the same enthusiasm, and even from a distance he remained an extraordinary example of an inspirational and generous mentor. This review is a sign of our gratitude to a mentor and a friend whom we deeply miss.

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanLymphoproliferative DisordersPrimary Immunodeficiency DiseasesReceptors, KIRHistory, 20th CenturyHistory, 21st CenturyHumansKiller Cells, NaturalReceptors, KIRfunctional assaysmonoclonal antibodiesnatural killer cellsprimary immunodeficienciessignaling transduction

Identifiers

PMID31396241
PMCPMC6668486
OpenAlexW2962267678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.